ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
82.3%
121M of 147M shares
Institutional holders
149
28 new, 14 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $1.36M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Adage Capital Management, L.P. | 9,627,304 | 9.00% | 13G (passive) | Dec 31, 2024 |
| Deep Track Biotechnology Master Fund, Ltd. | 9,345,000 | 7.00% | 13G (passive) | Mar 9, 2026 |
| Robert Atchinson | 8,201,344 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 7,879,943 | 5.40% | 13G (passive) | Sep 14, 2026 |
| BlackRock, Inc. | 6,700,629 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Israel A. Englander | 5,543,138 | 5.10% | 13G (passive) | Apr 28, 2025 |
| BML Investment Partners, L.P. | 13,950,000 | 9.90% | 13G (passive) amendment | Apr 23, 2026 |
| RA Capital Healthcare Fund, L.P. | 12,723,026 | 9.10% | 13G (passive) amendment | Jun 30, 2026 |
| Biosion, Inc. | 11,281,950 | 9.40% | 13G (passive) amendment | Dec 9, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACRS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,723,026 | 8.64% | $67.30M | +5,918,954 | 0.58% |
| BML Capital Management, LLC | 11,975,000 | 8.14% | $63.35M | −2,275,000 | 35.98% |
| BlackRock, Inc. | 10,037,008 | 6.82% | $53.10M | +2,629,943 | 0.00% |
| Deep Track Capital, LP | 9,345,000 | 6.35% | $49.44M | – | 0.72% |
| Vivo Capital, LLC | 6,694,637 | 4.55% | $35.41M | +27,971 | 3.23% |
| Vanguard Capital Management LLC | 5,817,866 | 3.95% | $30.78M | +650,397 | 0.00% |
| Frazier Life Sciences Management, L.P. | 4,925,374 | 3.35% | $26.06M | – | 0.57% |
| Rock Springs Capital Management LP | 4,330,532 | 2.94% | $22.91M | −142,118 | 1.12% |
| Adage Capital Partners Gp, L.L.C. | 4,071,000 | 2.77% | $21.54M | +200,000 | 0.03% |
| Decheng Capital LLC | 4,041,736 | 2.75% | $21.38M | – | 2.92% |
| Kalehua Capital Management LLC | 3,664,730 | 2.49% | $19.39M | +494,809 | 6.18% |
| State Street Corp | 3,255,340 | 2.21% | $17.22M | +1,246,594 | 0.00% |
| Geode Capital Management, LLC | 3,190,058 | 2.17% | $16.88M | +766,367 | 0.00% |
| Braidwell LP | 2,142,348 | 1.46% | $11.33M | +443,232 | 0.42% |
| Balyasny Asset Management L.P. | 2,023,470 | 1.37% | $10.70M | −1,337,858 | 0.01% |
| Silverarc Capital Management, LLC | 1,946,482 | 1.32% | $10.30M | New | 1.07% |
| Citadel Advisors LLC | 1,762,081 | 1.20% | $9.32M | −487,238 | 0.00% |
| Jones Hill Capital LP | 1,759,492 | 1.20% | $9.31M | New | 1.98% |
| Acadian Asset Management LLC | 1,641,472 | 1.12% | $8.68K | +101,681 | 0.01% |
| Palo Alto Investors LP | 1,613,430 | 1.10% | $8.54M | – | 1.18% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 121M | 82.3% | 28 / 68 | 31 / 14 | 22M | 11M |
| Q1 2026 | 136 | 111M | 75.1% | 33 / 41 | 40 / 16 | 44M | 9M |
| Q4 2025 | 122 | 84M | 56.9% | 25 / 34 | 40 / 6 | 7M | 10M |
| Q3 2025 | 103 | 86M | 58.7% | 15 / 26 | 40 / 7 | 6M | 12M |
| Q2 2025 | 96 | 92M | 62.4% | 23 / 29 | 29 / 36 | 13M | 14M |
| Q1 2025 | 109 | 93M | 63.0% | 23 / 39 | 27 / 12 | 15M | 10M |
| Q4 2024 | 98 | 88M | 59.4% | 34 / 25 | 24 / 15 | 46M | 9M |
| Q3 2024 | 81 | 51M | 34.6% | 9 / 21 | 28 / 25 | 6M | 6M |
| Q2 2024 | 98 | 53M | 35.9% | 24 / 20 | 38 / 24 | 10M | 13M |
| Q1 2024 | 98 | 56M | 37.7% | 18 / 27 | 39 / 27 | 13M | 17M |
| Q4 2023 | 107 | 60M | 40.4% | 24 / 41 | 26 / 53 | 26M | 37M |
| Q3 2023 | 137 | 70M | 47.8% | 20 / 61 | 34 / 16 | 10M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ACRS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,243,349 | 2.88% | $22.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,094,268 | 2.10% | $16.37M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,449,603 | 0.98% | $7.67M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,297,851 | 0.88% | $6.75M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 960,785 | 0.65% | $5.08M | 0.03% | Jun 30, 2026 |
| iShares Biotechnology ETF | 778,135 | 0.53% | $4.12M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 723,948 | 0.49% | $3.83M | 0.89% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 506,345 | 0.34% | $2.30M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 472,249 | 0.32% | $2.15M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 395,461 | 0.27% | $2.09M | 0.14% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 325,402 | 0.22% | $1.48M | 0.08% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 287,952 | 0.20% | $1.50M | 0.02% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 273,629 | 0.19% | $1.45M | 0.00% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 264,068 | 0.18% | $1.40M | 0.11% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 240,831 | 0.16% | $1.27M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neal Walker | CEO, Director | 1,543,886 | 1.05% | Feb 6, 2026 |
| Hugh M. Davis | President and COO, Director | 45,425 | 0.03% | Feb 6, 2026 |
| Roland Wilhelm Kolbeck | Chief Scientific Officer | 36,375 | 0.02% | Aug 4, 2026 |
| Jesse Wayne Hall | Chief Medical Officer | 27,045 | 0.02% | May 5, 2026 |
| Kevin Balthaser | Chief Financial Officer | 188,130 | 0.13% | Mar 3, 2026 |
| James Loerop | Chief Business Officer | 192,260 | 0.13% | Feb 6, 2026 |
| Joseph Monahan | Chief Scientific Officer | 265,855 | 0.18% | Mar 4, 2025 |
| Christopher P. Molineaux | Director | 69,536 | 0.05% | Jun 8, 2026 |
| William D. Humphries | Director | 45,105 | 0.03% | Jun 8, 2026 |
| Vincent Milano | Director | 28,896 | 0.02% | Jun 8, 2026 |
| Maxine Gowen | Director | 33,334 | 0.02% | Jun 8, 2026 |
| Anand Mehra | Director | 2,637,976 | 1.79% | Jun 8, 2026 |
| Andrew N. Schiff | Director | 459,995 | 0.31% | Jun 8, 2026 |
| Braden Michael Leonard | 10% owner | 13,950,000 | 9.48% | Apr 27, 2026 |
| Biosion, Inc. | 10% owner | – | – | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Roland Wilhelm Kolbeck Chief Scientific Officer | Aug 1, 2026 | Option exercise | +36,375 | – | – | 36,375 |
| Roland Wilhelm Kolbeck Chief Scientific Officer | Aug 1, 2026 | Tax withholding | −12,385 | $5.20 | $64.40K | 23,990 |
| William D. Humphries Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 45,105 |
| Anand Mehra Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 726,403 |
| Andrew N. Schiff Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 25,540 |
| Maxine Gowen Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 33,334 |
| Christopher P. Molineaux Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 69,536 |
| Vincent Milano Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 28,896 |
| Jesse Wayne Hall Chief Medical Officer | May 1, 2026 | Tax withholding | −9,330 | $4.41 | $41.15K | 27,045 |
| Jesse Wayne Hall Chief Medical Officer | May 1, 2026 | Option exercise | +36,375 | – | – | 36,375 |
| Braden Michael Leonard 10% owner | Apr 23, 2026 | Sale | −300,000 | $4.53 | $1.36M | 13,950,000 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2026 | Option exercise | +2,375 | – | – | 188,130 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2026 | Tax withholding | −677 | $2.87 | $1.94K | 187,453 |
| James Loerop Chief Business Officer | Feb 3, 2026 | Tax withholding | −5,937 | $3.47 | $20.60K | 192,260 |
| James Loerop Chief Business Officer | Feb 3, 2026 | Option exercise | +20,875 | – | – | 198,197 |
| Hugh M. Davis President and COO, Director | Feb 3, 2026 | Option exercise | +18,675 | – | – | 45,425 |
| Neal Walker CEO, Director | Feb 3, 2026 | Tax withholding | −18,611 | $3.47 | $64.58K | 1,543,886 |
| Neal Walker CEO, Director | Feb 3, 2026 | Option exercise | +63,475 | – | – | 1,562,497 |
| Kevin Balthaser Chief Financial Officer | Feb 3, 2026 | Tax withholding | −6,449 | $3.47 | $22.38K | 185,755 |
| Kevin Balthaser Chief Financial Officer | Feb 3, 2026 | Option exercise | +22,025 | – | – | 192,204 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +14,750 | – | – | 188,008 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +11,250 | – | – | 165,758 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Tax withholding | −10,686 | $3.51 | $37.51K | 177,322 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +7,500 | – | – | 173,258 |
| Kevin Balthaser Chief Financial Officer | Feb 1, 2026 | Option exercise | +14,750 | – | – | 175,163 |
| Kevin Balthaser Chief Financial Officer | Feb 1, 2026 | Tax withholding | −4,984 | $3.51 | $17.49K | 170,179 |
| Neal Walker CEO, Director | Jan 2, 2026 | Tax withholding | −9,952 | $2.88 | $28.66K | 1,499,022 |
| Neal Walker CEO, Director | Jan 2, 2026 | Option exercise | +29,150 | – | – | 1,508,974 |
| James Loerop Chief Business Officer | Jan 2, 2026 | Option exercise | +18,150 | – | – | 161,212 |
| James Loerop Chief Business Officer | Jan 2, 2026 | Tax withholding | −6,171 | $2.88 | $17.77K | 155,041 |
| Kevin Balthaser Chief Financial Officer | Jan 2, 2026 | Option exercise | +13,200 | – | – | 164,874 |
| Kevin Balthaser Chief Financial Officer | Jan 2, 2026 | Tax withholding | −4,461 | $2.88 | $12.85K | 160,413 |
| Kevin Balthaser Chief Financial Officer | Jan 1, 2026 | Option exercise | +7,500 | – | – | 153,924 |
| Kevin Balthaser Chief Financial Officer | Jan 1, 2026 | Tax withholding | −2,250 | $3.01 | $6.77K | 151,674 |
| James Loerop Chief Business Officer | Dec 31, 2025 | Option exercise | +73,750 | – | – | 177,056 |
| James Loerop Chief Business Officer | Dec 31, 2025 | Tax withholding | −33,994 | $3.01 | $102.32K | 143,062 |
| Kevin Balthaser Chief Financial Officer | Dec 31, 2025 | Tax withholding | −19,934 | $3.01 | $60.00K | 146,424 |
| Kevin Balthaser Chief Financial Officer | Dec 31, 2025 | Option exercise | +73,750 | – | – | 166,358 |
| Hugh M. Davis President and COO, Director | Dec 2, 2025 | Option exercise | +26,750 | – | – | 26,750 |
| Andrew N. Schiff Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 13,960 |
| Christopher P. Molineaux Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 57,956 |
| Maxine Gowen Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 21,754 |
| William D. Humphries Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 33,525 |
| Vincent Milano Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 17,316 |
| Anand Mehra Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 714,823 |
| Neal Walker CEO, Director | May 1, 2025 | Tax withholding | −2,975 | $1.38 | $4.11K | 1,479,824 |
| Neal Walker CEO, Director | May 1, 2025 | Option exercise | +9,467 | – | – | 1,482,799 |
| Neal Walker CEO, Director | Apr 1, 2025 | Option exercise | +9,467 | – | – | 1,476,374 |
| Neal Walker CEO, Director | Apr 1, 2025 | Tax withholding | −3,042 | $1.48 | $4.50K | 1,473,332 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Option exercise | +1,100 | – | – | 90,960 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Option exercise | +2,375 | – | – | 93,335 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Tax withholding | −727 | $1.99 | $1.45K | 92,608 |
| Neal Walker CEO, Director | Mar 1, 2025 | Option exercise | +9,466 | – | – | 1,470,184 |
| Neal Walker CEO, Director | Mar 1, 2025 | Tax withholding | −3,277 | $1.99 | $6.52K | 1,466,907 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Tax withholding | −27,258 | $1.99 | $54.24K | 265,662 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Option exercise | +10,925 | – | – | 292,920 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Option exercise | +50,000 | – | – | 281,995 |
| James Loerop Chief Business Officer | Feb 1, 2025 | Tax withholding | −15,980 | $2.48 | $39.63K | 102,773 |
| James Loerop Chief Business Officer | Feb 1, 2025 | Tax withholding | −15,980 | $2.48 | $39.63K | 102,773 |
| Joseph Monahan Chief Scientific Officer | Feb 1, 2025 | Option exercise | +14,750 | – | – | 243,312 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| B. Monahan Joseph Officer | Oct 23, 2023 | 6,000 | $31.68K | Oct 23, 2023 | Restricted Stock Units |
| B. Monahan Joseph Officer | Aug 21, 2023 | 6,000 | $42.90K | Aug 21, 2023 | Restricted Stock Units |
| B. Monahan Joseph Officer | Jun 20, 2023 | 6,000 | $61.32K | Jun 20, 2023 | Restricted Stock Units |